Published in
American Association for the Advancement of Science, Science Translational Medicine, 476(11), 2019
DOI: 10.1126/scitranslmed.aat9321
Links
Tools
Therapeutic targeting of the RB1 pathway in retinoblastoma with the oncolytic adenovirus VCN-01
Journal article published in 2019 by
Guillem Pascual-Pasto 
,
Miriam Bazan-Peregrino ,
Nagore G. Olaciregui,
Camilo A. Restrepo-Perdomo,
Ana Mato-Berciano,
Daniela Ottaviani,
Klaus Weber ,
Genoveva Correa,
Sonia Paco,
Monica Vila-Ubach,
Maria Cuadrado-Vilanova,
Helena Castillo-Ecija ,
Gaia Botteri ,
Laura Garcia-Gerique,
Helena Moreno-Gilabert
and other authors.
,
Miriam Bazan-Peregrino ,
Nagore G. Olaciregui,
Camilo A. Restrepo-Perdomo,
Ana Mato-Berciano,
Daniela Ottaviani,
Klaus Weber ,
Genoveva Correa,
Sonia Paco,
Monica Vila-Ubach,
Maria Cuadrado-Vilanova,
Helena Castillo-Ecija ,
Gaia Botteri ,
Laura Garcia-Gerique,
Helena Moreno-Gilabert
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 
Abstract
An oncolytic adenovirus shows antitumor efficacy in patient-derived models of intraocular retinoblastoma and appears safe for human use.